{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=28-day+levonorgestrel+oral+contraceptive",
    "query": {
      "intervention": "28-day levonorgestrel oral contraceptive"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=28-day+levonorgestrel+oral+contraceptive&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T12:51:28.375Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01291004",
      "title": "A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Follicle Development",
        "Ovarian Follicle",
        "Follicle Count",
        "Follicle Size",
        "Oral Contraceptive"
      ],
      "interventions": [
        {
          "name": "Desogestrel/ethinyl estradiol and ethinyl estradiol",
          "type": "DRUG"
        },
        {
          "name": "28-day drospirenone oral contraceptive",
          "type": "DRUG"
        },
        {
          "name": "28-day levonorgestrel oral contraceptive",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 206,
      "start_date": "2011-01-31",
      "completion_date": "2012-03-31",
      "has_results": false,
      "last_update_posted_date": "2021-12-08",
      "last_synced_at": "2026-10-02T12:51:28.375Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01291004"
    },
    {
      "nct_id": "NCT01252186",
      "title": "A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemostasis",
        "Oral Contraceptive"
      ],
      "interventions": [
        {
          "name": "91-day Levonorgestrel Oral Contraceptive",
          "type": "DRUG"
        },
        {
          "name": "28-day Levonorgestrel Oral Contraceptive",
          "type": "DRUG"
        },
        {
          "name": "28-day Desogestrel Oral Contraceptive",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Women's Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 265,
      "start_date": "2010-11",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2015-03-13",
      "last_synced_at": "2026-10-02T12:51:28.375Z",
      "location_count": 21,
      "location_summary": "San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01252186"
    },
    {
      "nct_id": "NCT02846142",
      "title": "Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "PTI-428",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "ethinyl estradiol and levonorgestrel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Proteostasis Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 94,
      "start_date": "2016-06",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2018-05-24",
      "last_synced_at": "2026-10-02T12:51:28.375Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02846142"
    },
    {
      "nct_id": "NCT01963403",
      "title": "Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Abnormal Uterine Bleeding, Unspecified",
        "Uterine Bleeding Heavy"
      ],
      "interventions": [
        {
          "name": "EE 30mcg/LNG 150mcg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "14 Years and older · Female only"
      },
      "enrollment_count": 26,
      "start_date": "2013-12",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-05-12",
      "last_synced_at": "2026-10-02T12:51:28.375Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • St Louis, Missouri",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01963403"
    },
    {
      "nct_id": "NCT04142762",
      "title": "A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "ABI-H2158",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Ethinyl Estradiol / Levonorgestrel",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching oral contraceptive",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Assembly Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2019-10-18",
      "completion_date": "2020-01-29",
      "has_results": false,
      "last_update_posted_date": "2020-03-04",
      "last_synced_at": "2026-10-02T12:51:28.375Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04142762"
    },
    {
      "nct_id": "NCT01236768",
      "title": "Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Contraception"
      ],
      "interventions": [
        {
          "name": "AG200-15",
          "type": "DRUG"
        },
        {
          "name": "Levora",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agile Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 407,
      "start_date": "2010-10",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2017-09-15",
      "last_synced_at": "2026-10-02T12:51:28.375Z",
      "location_count": 21,
      "location_summary": "Mobile, Alabama • Green Valley, Arizona • Tucson, Arizona + 16 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Green Valley",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01236768"
    },
    {
      "nct_id": "NCT01546454",
      "title": "Relationship Between the Menstrual Cycle and Heart Disease in Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Heart Disease"
      ],
      "interventions": [
        {
          "name": "Ethinyl Estradiol-Levonorgestrel combination",
          "type": "DRUG"
        },
        {
          "name": "leuprolide acetate",
          "type": "DRUG"
        },
        {
          "name": "Estradiol",
          "type": "DRUG"
        },
        {
          "name": "Progesterone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 40 Years · Female only"
      },
      "enrollment_count": 5,
      "start_date": "2012-02",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-22",
      "last_synced_at": "2026-10-02T12:51:28.375Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01546454"
    },
    {
      "nct_id": "NCT00394771",
      "title": "A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breakthrough Bleeding"
      ],
      "interventions": [
        {
          "name": "DR-1031",
          "type": "DRUG"
        },
        {
          "name": "Seasonale®",
          "type": "DRUG"
        },
        {
          "name": "Portia®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duramed Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 567,
      "start_date": "2006-10",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2013-07-26",
      "last_synced_at": "2026-10-02T12:51:28.375Z",
      "location_count": 50,
      "location_summary": "Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00394771"
    },
    {
      "nct_id": "NCT00117273",
      "title": "A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]",
          "type": "DRUG"
        },
        {
          "name": "Seasonique (LNG/EE and EE)",
          "type": "DRUG"
        },
        {
          "name": "Portia (LNG/EE)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duramed Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 36,
      "start_date": "2005-06",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2014-05-09",
      "last_synced_at": "2026-10-02T12:51:28.375Z",
      "location_count": 1,
      "location_summary": "Temple, Texas",
      "locations": [
        {
          "city": "Temple",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00117273"
    },
    {
      "nct_id": "NCT00924560",
      "title": "A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bone Mineral Density"
      ],
      "interventions": [
        {
          "name": "91-day Levonorgestrel Oral Contraceptive",
          "type": "DRUG"
        },
        {
          "name": "28-day Levonorgestrel Oral Contraceptive",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duramed Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 18 Years · Female only"
      },
      "enrollment_count": 1361,
      "start_date": "2009-06",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-10-22",
      "last_synced_at": "2026-10-02T12:51:28.375Z",
      "location_count": 46,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 39 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00924560"
    }
  ]
}